Biotech entity
All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention CNBC, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Drug Enforcement Administration, all published on August 16, 2026.
Last mentioned: Aug 16, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention CNBC, the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Biotech story that mention Drug Enforcement Administration, all published on August 16, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 7 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Drug Enforcement Administration. Shared-story counts are live from our verified record — not editorial picks.
Biotech and pharma teams evaluating cannabinoid-derived drugs face unsettled federal scheduling and reimbursement policy. MMJ's litigation could alter DEA and CMS pathways through stay, remand, or vacatur.
Source: finanznachrichten.de · pr-inside.com
Drug Enforcement Administration is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
